Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Radium Ra-223 Dichloride in Castration-sensitive prostate cancer: NCT07717099 Clinical Landscape Report 2026
18 September 2026
NCT07717099 clinical landscape for Castration-sensitive prostate cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Febuxostat in Kidney Diseases: PACTR202607678798356 Clinical Landscape Report 2026
18 September 2026
PACTR202607678798356 clinical landscape for Kidney Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Remimazolam Tosylate in Colorectal Cancer: NCT07740343 Clinical Landscape Report 2026
18 September 2026
NCT07740343 clinical landscape for Colorectal Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Orforglipron in Diabetes Mellitus, Type 2: NCT07739537 Clinical Landscape Report 2026
18 September 2026
NCT07739537 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Semaglutide (Novo Nordisk) in Localized Prostate Carcinoma: NCT07727473 Clinical Landscape Report 2026
18 September 2026
NCT07727473 clinical landscape for Localized Prostate Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sintilimab in Adenocarcinoma of Lung: NCT07748325 Clinical Landscape Report 2026
18 September 2026
NCT07748325 clinical landscape for Adenocarcinoma of Lung: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Amivantamab-VMJM in Metastatic Malignant Neoplasm to the Leptomeninges: NCT07744529 Clinical Landscape Report 2026
18 September 2026
NCT07744529 clinical landscape for Metastatic Malignant Neoplasm to the Leptomeninges: endpoints, sponsor, phase, geography, readouts, asset context and deve…
9 min read
Paclitaxel in Extensive stage Small Cell Lung Cancer: NCT07744698 Clinical Landscape Report 2026
18 September 2026
NCT07744698 clinical landscape for Extensive stage Small Cell Lung Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development whit…
9 min read
Fulvestrant in PIK3CA mutation/HR-positive/HER2-negative Breast Cancer: NCT07748208 Clinical Landscape Report 2026
18 September 2026
NCT07748208 clinical landscape for PIK3CA mutation/HR-positive/HER2-negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and…
9 min read
Ubidecarenone in Noninsulin-Dependent Diabetes Mellitus With Deafness: NCT07748130 Clinical Landscape Report 2026
18 September 2026
NCT07748130 clinical landscape for Noninsulin-Dependent Diabetes Mellitus With Deafness: endpoints, sponsor, phase, geography, readouts, asset context and de…
9 min read
Cemiplimab-RWLC in Resectable Lung Non-Small Cell Carcinoma: NCT07746388 Clinical Landscape Report 2026
18 September 2026
NCT07746388 clinical landscape for Resectable Lung Non-Small Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
Icodec Insulin in Diabetes Mellitus, Type 2: NCT07747402 Clinical Landscape Report 2026
18 September 2026
NCT07747402 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white space.